Background {#Sec1}
==========

Red cell distribution width (RDW), a coefficient of variation in red blood cell (RBC) volume, is routinely available in reports of complete blood count. RDW is commonly increased because of erythropoiesis deficits or accelerated RBC destruction. RDW increase is often considered as an indicator of anemia caused by iron, cobalamin, or folate deficiency \[[@CR1], [@CR2]\]. Recent studies have indicated that patients with higher RDW levels were associated with an increased risk of cardiovascular (CV) events and new-onset stroke \[[@CR3]--[@CR5]\]. Moreover, the level of RDW was positively correlated with mortality in patients with acute or critical illnesses, in those with chronic diseases, and in healthy cohorts \[[@CR6]--[@CR13]\]. Patel et al. reported a 14% increased risk of death for each 1% increment in RDW in a community-based elderly population \[[@CR10]\].

Chronic kidney disease (CKD) and anemia are well-known risk factors for CV events and mortality. RDW significantly increases when CKD progresses from stage 1 to stage 5 \[[@CR14]\]. According to our review of the relevant literature, few reports have focused on RDW in patients with CKD. Hsieh et al. revealed that RDW was an independent predictor of all-cause mortality, cardiovascular mortality, and infection mortality in CKD stages 3--5 \[[@CR15]\]. Inadequate erythropoietin production is the primary feature of anemia in patients with CKD. Anemia reduces oxygen delivery and increases cardiac workload, which exacerbates heart failure and increases the risk of CV events. However, anemia is not the only possible explanation of elevated RDW in patients with CKD. The association of RDW with CV events and mortality was observed to be significant after adjustment for hemoglobin \[[@CR16]\]. In this study, we investigated the effect of RDW on major composite CV outcomes during CKD stages 1--5. We hypothesized that elevated RDW is an independent risk factor for CV events and mortality in patients with CKD.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

This study was conducted by retrospectively analyzing consecutive patients who were admitted to the Department of Cardiology at Chang Gung Memorial Hospital (a tertiary medical center) in Taiwan, from January 2011 to December 2011. Patients with CKD who were hospitalized for coronary artery disease (CAD) were enrolled on the date of admission. CKD was diagnosed using the existing anatomical abnormality of the kidney, persistent proteinuria, hematuria, or an estimated glomerular filtration rate of \<90 mL/min/1.73 m^2^ for more than 3 months. We excluded patients who are aged \<20 years and those who had end-stage renal disease on long-term renal replacement therapy. The Institutional Review Board at Linkou Chang Gung Memorial Hospital approved this study and waived the requirement for informed consent.

Data collection {#Sec4}
---------------

Normal RDW was defined as a level of 11.5%--14.5%. Patients were divided into normal RDW (RDW \< 14.5%) and elevated RDW (RDW ≥ 14.5%) groups. We retrieved their demographic characteristics; comorbidities; blood investigation results; and prescriptions of antiplatelet agents, angiotensin converting enzyme inhibitor/angiotensin II receptor blockers, beta blockers, and statins. Patients were followed up for 3 years. The primary endpoint of this study was to elucidate the effect of RDW on mortality and major composite CV events, defined as re-admission for CAD or congestive heart failure during the follow-up period. The secondary endpoints were the identification of independent predictors of major composite CV outcomes in patients with CKD and determination of the variation in RDW among different CKD stages. The follow-up ended when a major composite CV event or death occurred, or when the patient remained event free till 3 years.

Statistical analysis {#Sec5}
--------------------

Data are presented as mean ± standard deviation for continuous data and number (percentage) for categorical data. The 2 groups (RDW \< 14.5% vs RDW ≥ 14.5%) were compared using a 2-sample *t* test for continuous variables and the Fisher exact test for categorical variables. The linear trend of RDW across groups of CKD stages was evaluated using a linear contrast test in a general linear model.

We used different multivariable Cox proportional hazard models to evaluate the association between RDW and primary outcomes. Various confounding factors, including demographic variables, comorbidities, and serum lipids, were further adjusted in the models. In addition to adjusting for variables related to the Framingham cardiovascular risk score, we adjusted for baseline characteristics that presented a significant difference between the 2 groups in the multivariable models (*P* \< .05). The following models were used: (1) unadjusted model; (2) model adjusted for age and sex; (3) model further adjusted for diabetes mellitus (DM), hypertension (HTN), and smoking; (4) model further adjusted for total cholesterol, high-density lipoprotein (HDL), and systolic blood pressure (BP); (5) model further adjusted for hemoglobin and albumin; and (6) model further adjusted for creatinine and left ventricular ejection fraction (LVEF).

The cumulative survival curves for major composite CV outcomes during the 3-year follow-up period were generated using the Kaplan--Meier method, whereas the difference between the 2 groups was evaluated using a log-rank test. A *P* value of \<.05 was considered statistically significant. This study used IBM SPSS 22 (IBM SPSS, Armonk, NY, USA: IBM Corp) for data analysis.

Results {#Sec6}
=======

A total of 282 patients with CKD who were admitted for CAD in 2011 were enrolled in this study. Patients were divided into normal RDW (RDW \< 14.5%; *n* = 213) and elevated RDW (RDW ≥ 14.5%, *n* = 69) groups. The baseline characteristics of the study cohort are presented in Table [1](#Tab1){ref-type="table"}. The elevated RDW group had older patients than did the normal RDW group (68.2 ± 13.1 vs 63.7 ± 13.8, *P* = .018) and also had a lower proportion of male patients (62.3% vs 77.9%, *P* = .017). Moreover, patients in the elevated RDW group presented significantly lower left ventricular ejection fraction (LVEF; 48.4 ± 18.4 vs 55.6 ± 15.7, *P* = .017), lower hemoglobin levels (11.3 ± 2.1 vs 13.4 ± 2.3, *P* \< .001), lower serum albumin levels (3.6 ± 0.5 vs 3.8 ± 0.5, *P* = .005), and higher creatinine levels (1.89 ± 1.58 vs 1.31 ± 0.93, *P* \< .001), compared with those in the normal RDW group. The baseline characteristics of the 2 groups were similar in terms of comorbidities, systolic and diastolic BP, leukocyte count, platelet count, alanine aminotransferase levels, sodium levels, potassium levels, sugar levels, total cholesterol levels, low-density lipoprotein levels, HDL levels, and medications. During the 3-year follow-up period, the elevated RDW group exhibited a higher incidence of major composite CV outcomes (46.4% vs 17.8%, *P* \< .001). No statistical difference was observed; however, a trend toward higher mortality was noted in the elevated RDW group (10.1% vs 3.8%, *P* = .059).Table 1Baseline characteristics of patients according to RDWCharacteristicsRDW \< 14.5% (*n* = 213)RDW ≥ 14.5% (*n* = 69)*P* ^‡^Age, year63.7 ± 13.868.2 ± 13.10.018Male gender, n (%)166 (77.9)43 (62.3)0.017Diabetes mellitus, n (%)85 (39.9)35 (50.7)0.125Hypertension, n (%)135 (63.4)43 (62.3)0.887Old CVA, n (%)21 (9.9)5 (7.2)0.636Smoker, n (%)80 (37.6)34 (49.3)0.092Systolic BP, mmHg125.2 ± 25.6129.0 ± 29.20.293Diastolic BP, mmHg70.3 ± 15.666.2 ± 14.40.056LVEF, %55.6 ± 15.748.4 ± 18.40.002Lab data Leukocyte count, 1000/ml9.9 ± 3.39.6 ± 3.00.492 Hemoglobin, g/dl13.4 ± 2.311.3 ± 2.1\<0.001 Platelet count, 1000/ml209.6 ± 60.3207.3 ± 84.00.811 ALT, u/l40.5 ± 41.532.8 ± 44.00.185 Albumin, mg/dl3.8 ± 0.53.6 ± 0.50.005 Creatinine, mg/dl1.31 ± 0.931.89 ± 1.58\<0.001 Na, mmol/L139.4 ± 3.3138.8 ± 3.50.212 K, mmol/L3.9 ± 0.54.0 ± 0.50.416 Sugar, mg/dl162.6 ± 77.5155.0 ± 73.00.477 Total cholesterol, mg/dL197.1 ± 37.5198.9 ± 37.90.721 LDL, mg/dL109.5 ± 32.4111.6 ± 31.30.649 HDL, mg/dL42.7 ± 12.746.1 ± 16.00.068Medications, n (%) Anti-platelet agents207 (97.2)66 (95.7)0.461 Beta-blocker202 (94.8)63 (91.3)0.380 ACEi/ARB182 (85.4)54 (78.3)0.189 Statin196 (92.0)62 (89.9)0.621Outcomes, n (%) Mortality8 (3.8)7 (10.1)0.059 Major composite CV outcome38 (17.8)32 (46.4)\<0.001*RDW* red cell distribution width, *CVA* cerebrovascular accident, *BP* blood pressure, *LEVF* left ventricular ejection fraction, *ALT* alanine aminotransferase, *LDL* low-density lipoprotein, *HDL* high-density lipoprotein, *ACEi* angiotensin converting enzyme inhibitor, *ARB* angiotensin II receptor blocker, *CV* cardiovascular^‡^Continuous variables were compared using a *t* test and categorical variables were compared using the Fisher exact test

We analyzed the RDW levels across CKD stages (Fig. [1](#Fig1){ref-type="fig"}). RDW increased when renal function deteriorated from CKD stage 1 to stage 5. We also observed a linear trend toward higher RDW after stratifying patients according to their CKD stage (*P* for linear trend \< .001).Fig. 1RDW levels in groups across CKD stages

Table [2](#Tab2){ref-type="table"} presents the associations between RDW and the risk of major composite CV outcomes during the 3-year follow-up period in the 6 models. In the unadjusted model, RDW ≥ 14.5% was associated with an increased risk of major composite CV outcomes (Hazard ratio \[HR\], 3.22, 95% confidence interval \[CI\], 2.01--5.15). We first adjusted the variables of the Framingham CV risk score, including age, sex, diabetes, HTN, smoking, total cholesterol, HDL, and systolic BP. The association was significant after adjustment for age and sex (model 2: HR, 3.15; 95% CI, 1.94--5.12); further adjustment for DM, HTN, and smoking (model 3: HR, 3.14; 95% CI, 1.92--5.13); and further adjustment for total cholesterol levels, HDL levels, and systolic BP (model 4: HR, 3.25; 95% CI, 1.99--5.31). We then adjusted for demographic variables that exhibited a significant difference (Table [1](#Tab1){ref-type="table"}): hemoglobin, albumin, creatinine, and LVEF levels in models 5 and 6. Despite the adjustments for hemoglobin and albumin levels (model 5: HR, 2.83; 95% CI, 1.70--4.70) and further adjustment for creatinine and LVEF levels (model 6: HR, 2.58; 95% CI, 1.54--4.32), RDW ≥ 14.5% was independently associated with a higher risk of major composite CV outcomes in patients with CKD.Table 2Association between RDW and risk of major composite cardiovascular outcomes in various adjustment modelsModelPresence of RDW ≥ 14.5%HR95% CI of HR*P* valueModel 1, unadjusted model3.222.01--5.15\<0.001Model 2, adjusted for age, gender3.151.94--5.12\<0.001Model 3, further adjusted for diabetes mellitus, hypertension, smoking3.141.92--5.13\<0.001Model 4, further adjusted for total cholesterol, HDL, Systolic BP3.251.99--5.31\<0.001Model 5, further adjusted for hemoglobin, albumin2.831.70--4.70\<0.001Model 6, further adjusted for creatinine, LVEF2.581.54--4.32\<0.001*RDW* red cell distribution width, *HR* hazard ratio, *CI* confidence interval, *HDL* high-density lipoprotein, *BP* blood pressure, *LEVF* left ventricular ejection fraction

Major composite CV events developed in 32 of the 69 patients in the RDW ≥ 14.5% group (46.4%) and 38 of 213 patients (17.8%) in the elevated RDW group during the 3-year follow-up period. The Kaplan--Meier survival curves of major composite CV outcomes according to RDW status are presented in Fig. [2](#Fig2){ref-type="fig"}. Patients in the elevated RDW group exhibited significantly lower event-free survival (*P* value of log rank test \< .001).Fig. 2Kaplan--Meier survival curves of major composite CV outcomes during a 3-year follow-up period according to RDW levels

In the final multivariable model (model 6 in Table [2](#Tab2){ref-type="table"}), RDW ≥ 14.5% (HR, 2.581; 95% CI, 1.541--4.322) and older age (HR, 1.022; 95% CI, 1.001--1.043) were associated with an increased risk of major composite CV outcomes (Table [3](#Tab3){ref-type="table"}). However, higher LVEF values were associated with a lower CV risk (HR, 0.975; 95% CI, 0.961--0.989).Table 3Factors associated with major composite CV outcomes during a 3-year follow-up periodVariableHR95% CI of HR*P* valueRDW ≥ 14.5%2.5811.541--4.322\<0.001Age (year)1.0221.001--1.0430.037Male gender1.5870.849--2.9640.148Diabetes mellitus0.9710.580--1.6270.911Hypertension1.0040.566--1.7810.989Smoking0.9070.552--1.4910.701Total cholesterol (mg/dL)1.0010.995--1.0070.683HDL (mg/dL)0.9870.969--1.0060.174Systolic BP (mmHg)1.0010.991--1.0110.873Hemoglobin (g/dl)0.9410.823--1.0760.373Albumin (mg/dl)0.8440.489--1.4590.545Creatinine (mg/dl)1.1130.914--1.3550.286LVEF, %0.9750.961--0.9890.001*CV* cardiovascular, *HR* hazard ratio, *CI* confidence interval, *RDW* red cell distribution width, *HDL* high-density lipoprotein, *BP* blood pressure, *LEVF* left ventricular ejection fraction

Discussion {#Sec7}
==========

In this study, we investigated the association of RDW with major composite CV outcomes and mortality in patients with CKD. The elevated RDW group had older patients, a lower proportion of male patients, lower LVEF levels, lower hemoglobin levels, lower albumin levels, and higher serum creatinine levels compared with the normal RDW group. RDW levels exhibited a graded increase across different stages of CKD. RDW ≥ 14.5% was associated with a significantly higher incidence of major composite CV outcomes and a trend toward higher mortality. A greater than 2-fold risk of major composite CV outcomes was observed in the elevated RDW group (HR = 2.581, CI = 1.541--4.322, *P* \< .001). Age and impaired LVEF were additional covariates that were independent predictors of major composite CV outcomes in patients with CKD. The incidence of outcomes is higher than that reported in a previous study, because our patients were confirmed to have CAD \[[@CR15]\].

Patients with higher RDW levels are often considered to have erythropoietic stress. In the general population, patients with higher RDW levels are likely to be older and have smoking habits, higher body mass index, lower hemoglobin levels, lower mean corpuscular volume, and higher serum creatinine levels \[[@CR12], [@CR16], [@CR17]\]. Elevated RDW was correlated with higher serum levels of N-terminal pro-B-type natriuretic peptide (NT-proBNP), a larger left atrium, and lower LVEF values in patients with CV risk \[[@CR5], [@CR18]\]. RDW levels were also positively associated with C-reactive protein, the erythrocyte sedimentation rate, ferritin, and fibrinogen and negatively associated with albumin levels \[[@CR6], [@CR12], [@CR14], [@CR17]\]. Consequently, RDW was supposed to be a marker of inflammation, oxidative stress, and nutritional status \[[@CR9], [@CR19]\].

The pathophysiology of elevated RDW toward unfavorable CV outcomes has not been elucidated. Anemia and elevated serum creatinine, commonly occurring in patients with CKD, were risk factors for CV events. Our results reveal that the effect of RDW on major composite CV outcomes was independent of hemoglobin and creatinine levels. This finding is consistent with those of previous studies, which have reported that the level of RDW, even within the normal reference range, was associated with a higher risk of CV events and mortality irrespective of anemia, ferritin levels, and renal impairment \[[@CR9], [@CR10], [@CR13]--[@CR17]\]. There should be other explanations for the poor prognostic effect of RDW on major composite CV outcomes in patients with CKD. Two novel risk factors for CV events, oxidative stress and inflammation, could be possible underlying mechanisms.

Oxidative stress and inflammation suppress erythropoiesis and shorten RBC survival, resulting in heterogeneity in the size of circulating erythrocytes (also called anisocytosis). Human erythrocyte damage starts during the initial stages of oxidative stress \[[@CR20]\]. A low level of serum selenium, an essential trace element involved in the antioxidant system, was an independent predictor of higher RDW in community-dwelling adults \[[@CR21]\]. Serum interleukin-6 (IL-6), a proinflammatory cytokine, was positively correlated with RDW in adult patients with heart failure and congenital heart disease \[[@CR22], [@CR23]\]. IL-6 stimulates hepatic hepcidin expression, which inhibits duodenal iron absorption and induces ferritin transcription, thus increasing iron storage within macrophages \[[@CR24]\]. Inflammatory cytokines such as interferon-γ, tumor necrosis factor-α, interleukin-1, and interleukin-10 might compromise iron metabolism, impair erythroid progenitor cell proliferation, and blunt erythropoietin response to anemia \[[@CR24]\]. We supposed that elevated RDW could reflect oxidative and inflammatory stress, which is correlated with the risk of CV events and mortality \[[@CR12], [@CR23]\]. In a small randomized trial of patients undergoing hemodialysis, the use of a vitamin E-bonded cellulose membrane dialyzer, which was supposed to provide an antioxidant effect, reduced RDW levels and improved atherosclerosis \[[@CR25]\]. This hypothesis must be investigated further in the future.

Recent studies have demonstrated that elevated RDW was associated with renin--angiotensin--aldosterone system (RAAS) activation, autonomic regulation, malnutrition, and endothelial dysfunction. Erythropoiesis has been proven to be associated with chronic activation of the RAAS and could be influenced by catecholamine \[[@CR26]--[@CR29]\]. Vashistha et al. reported that for every 1 g/dL increase in the albumin level, RDW decreased by 0.7%. Solak et al. revealed that a higher RDW level was independently associated with impaired endothelial function and increased carotid intima media thickness in patients with CKD \[[@CR14]\]. In addition, RDW was associated with an abnormal pattern of circadian BP variation. RDW was higher in patients designated as nondippers compared with those designated as dippers \[[@CR30]\]. These characters are well-described risk factors for CV events and might be possible pathways underlying the association between RDW and CV outcomes. Additional studies are warranted to verify these potential mechanisms.

The association between RDW and mortality was linear and consistent across various RDW levels, ranging from the normal reference level to RDW ≥ 17.5% \[[@CR6], [@CR16]\]. We demonstrate the prognostic significance of RDW in this study. Because biomarkers of oxidative stress and inflammation such as myeloperoxidase, IL-6, and interferon-γ are not routinely available in general practice, RDW might be a cost-effective tool for physicians for identifying populations at high CV risks. However, similar to other markers of infection or inflammation, RDW is not specific for a particular disease. Therefore, the feasibility of its use in clinical applications remains unclear.

Some limitations of our study must be discussed. First, because we retrospectively analyzed our study cohort, we could determine only the association between increased RDW and CV outcomes but not the causality. Second, the study was conducted at a single center and included a relatively small number of patients; hence, our sample might not reflect the entire cohort. Third, although we controlled for several variables influencing RDW, there might be relevant confounders that we were unable to completely adjust. A well-designed prospective study with a larger cohort may be performed to verify our results.

Conclusions {#Sec8}
===========

In patients with CKD, a linear trend toward higher RDW was observed with the progress of the disease. Our results suggest RDW to be an indicator of CV events in patients with CKD during a 3-year follow-up period. Moreover, old age and decreased LVEF were additional risk factors for CV events. Oxidative stress and inflammation could be possible pathways underlying the association between RDW and unfavorable CV outcomes. Moreover, RAAS activation, autonomic regulation, malnutrition, and endothelial dysfunction might be potential mechanisms.
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